Saturday 17 October 2026
Export CURX’s income statement to Excel — free account
Curanex Pharmaceuticals Inc
CURX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 4,671.4% and free cash flow fell 272.3%, each against the same quarter a year earlier.
4.62
0.21
−4.35%
Follow CURX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+5 more quarters Free account |
77.52 | 81.95 | 62.89 | 45.95 |
Net Debt/EBITDA |
6.23 | 1.63 | 1.28 | 0.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
9.63 | 0.28 | 0.30 | 0.33 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(232.02) | — | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(7.18) | (0.67) | (0.67) | (0.76) | |
Cash per Share |
4.56 | 3.90 | 2.84 | 2.07 | |
Shareholders Equity per Share |
11.17 | 8.80 | 5.70 | 3.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.17 | 8.80 | 5.70 | 3.38 | |
Free Cash Flow |
(9.19) | (0.86) | (0.95) | (1.08) | |
Working Capital |
14.23 | 11.09 | 7.97 | 4.69 | |
Net Current Asset Value |
14.23 | 10.87 | 7.76 | 4.51 | |
| Other line items | |||||
Quick Ratio |
31.35 | 36.30 | 31.22 | 28.17 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.18) | (0.67) | (0.67) | (0.76) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
— | — | 0.01 | 0.00 | |
Average Assets |
7.24 | 5.79 | 4.21 | 2.93 | |
Average Common Equity |
— | — | 4.29 | 2.55 |
Columns are period end dates